Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly

Mails Letter to Stockholders Highlighting the Certainty of Value the Transaction Delivers to Stockholders Compared to a LiquidationREDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy as a potential One And DoneTM treatment to preserve sight for life, today announced that it has mailed a letter to its stockholders in connection with its pending transaction to be acquired by Eli Lilly and ...